Home › Lymphoma
Pag-aaral pangklinika para sa Lymphoma na nagre-recruit sa U.S.
142 pag-aaral para sa Lymphoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX34 pag-aaral
- Boston, MA33 pag-aaral
- New York City, NY33 pag-aaral
- Washington, DC23 pag-aaral
- Baldwin Park, CA21 pag-aaral
- Chicago, IL20 pag-aaral
- Durham, NC17 pag-aaral
- Philadelphia, PA15 pag-aaral
- St. Louis, MO15 pag-aaral
- Cleveland, OH13 pag-aaral
- Edison, NJ12 pag-aaral
- Seattle, WA12 pag-aaral
- Miami, FL11 pag-aaral
- Atlanta, GA11 pag-aaral
- Columbus, OH11 pag-aaral
- Rochester, MN11 pag-aaral
- Nashville, TN11 pag-aaral
- Salt Lake City, UT10 pag-aaral
- Queens, NY10 pag-aaral
- Los Angeles, CA10 pag-aaral
- Dallas, TX10 pag-aaral
- Pittsburgh, PA10 pag-aaral
- Milwaukee, WI9 pag-aaral
- Greenburgh, NY9 pag-aaral
- Mountain View, CA9 pag-aaral
- Denver, CO9 pag-aaral
- Aurora, CO8 pag-aaral
- Cincinnati, OH8 pag-aaral
- East Norwalk, CT8 pag-aaral
- Staten Island, NY8 pag-aaral
- Birmingham, AL8 pag-aaral
- Portland, OR8 pag-aaral
- New Rochelle, NY7 pag-aaral
- San Antonio, TX7 pag-aaral
- Tampa, FL7 pag-aaral
- Phoenix, AZ7 pag-aaral
- New Haven, CT7 pag-aaral
- Omaha, NE7 pag-aaral
- Kansas City, MO6 pag-aaral
- San Francisco, CA6 pag-aaral
Ayos sa estado
- Alabama9 pag-aaral
- Arizona11 pag-aaral
- Arkansas3 pag-aaral
- California40 pag-aaral
- Colorado16 pag-aaral
- Connecticut7 pag-aaral
- District of Columbia7 pag-aaral
- Florida25 pag-aaral
- Georgia15 pag-aaral
- Illinois23 pag-aaral
- Indiana6 pag-aaral
- Iowa6 pag-aaral
- Kansas7 pag-aaral
- Kentucky5 pag-aaral
- Maryland21 pag-aaral
- Massachusetts33 pag-aaral
- Michigan12 pag-aaral
- Minnesota14 pag-aaral
- Missouri17 pag-aaral
- Nebraska7 pag-aaral
- New Jersey18 pag-aaral
- New York42 pag-aaral
- North Carolina22 pag-aaral
- Ohio28 pag-aaral
- Oklahoma4 pag-aaral
- Oregon8 pag-aaral
- Pennsylvania24 pag-aaral
- South Carolina4 pag-aaral
- Tennessee15 pag-aaral
- Texas45 pag-aaral
- Utah13 pag-aaral
- Virginia10 pag-aaral
- Washington12 pag-aaral
- Wisconsin12 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07583810Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
Nagre-recruitObservasyonal na pag-aaral
Edad 3 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT01441089Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Nagre-recruitPhase 1/2
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT03223610A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07013435Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT00006518Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 110 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT00923507Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT03418038Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07014293A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Nagre-recruitPhase 1/2
Hanggang edad 25 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT04094610Epco, Zanu, Ritux for R/R FL or MZL
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06563596Rutgers University Study of the Genetics of Blood Cancers
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 110 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07714044Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Nagre-recruitPhase 1
24 Months – 18 Years · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06441331Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT02974647CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
Nagre-recruitPhase 2
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Set 24, 2026 · NCT04083495Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Nagre-recruitMaagang Phase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06398457A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07015242Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT04301076Precise Oncology Interventions in Nutrition and Training (OnPoint)
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT06534918Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
Nagre-recruitPhase 2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT03258567A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07221500Collection of Tissue Samples for Cancer Research
Nagre-recruitObservasyonal na pag-aaral
2 Months · Lahat ng kasarian · Na-update Set 16, 2026 · NCT00900198Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Nagre-recruitPhase 1
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Set 15, 2026 · NCT05798897AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT06137144CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Nagre-recruitPhase 1/2
12 Months – 21 Years · Lahat ng kasarian · Na-update Set 11, 2026 · NCT04870944A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT06624085Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.